In the August 2018 issue, the News Analysis “CD47 checkpoint data supercharge Stanford spinout IPO” described ongoing trials for drugs targeting CD47. However, the article omitted mention of a clinical trial with an anti-CD47 antibody from Tioma Therapeutics, which was terminated on the death of the first patient dosed. This fatality, potentially ascribed to red cell agglutination, may have some bearing on other trials with anti-CD47 antibodies.
Rights and permissions
About this article
Cite this article
Correction. Nat Biotechnol 36, 915 (2018). https://doi.org/10.1038/nbt1018-915b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1018-915b